Last week, England’s National Health Service released a commissioning framework for biological medicines, including biosimilars.
Last week, England’s National Health Service (NHS) released a commissioning framework for biological medicines, including biosimilars.
The framework, authored by the NHS’ Medicines, Diagnostics, Personalized Medicine Policy Team, explains that NHS England spent £16.8 billion ($21.6 billion) on medicines from 2015 to 2016, an 8% increase in spending over the prior year. Of the top 10 medicines prescribed, 6 are biologics. Using biosimilars could save the health system £200 million to £300 million ($270 million to $404 million) per year by 2020 to 2021, and those savings could be used to fund innovative treatments or improvements in care.
The framework proposes that at least 90% of new patients be prescribed the “best value biological medicine” within 3 months of the launch of a biosimilar for a given reference product, and that 80% of existing patients be prescribed the “best value” medicine within 12 months of a biosimilar’s launch.
The authors point to the NHS’ successes with biosimilars over the past 10 years; 80% of NHS patients receiving infliximab are now treated with a biosimilar, and 58% of patients receiving etanercept are treated with a biosimilar. The cost savings achieved by the health system through using these biosimilar options total £160 million ($216 million) per year. However, uptake of biosimialrs has been uneven in England; the framework indicates that 2 NHS trusts, both located in London, had uptake levels of biosimilar infliximab of 25% and 99%. This difference in rates shows, the authors say, a “significant opportunity” to improve uptake of biosimilar medicines.
With biosimilar rituximab now available in the European Union, and with biosimilars of trastuzumab and adalimumab expected to be available in December 2017 and October 2018, respectively, “It is now important for the NHS to embed the principles of switching to the best value biological medicine into commissioning and clinical practice, if we are to [realize] the optimal rate and extent of savings associated with these medicines,” say the authors.
The framework calls upon NHS commissioners to work with relevant stakeholders, including regional pharmacists and procurement specialists, and to partner with Regional Medicines Optimisation Committees (RMOCs) across England. RMOCs will coordinate with local providers to increase the use of the best value biologics, and will ensure that plans to transition to such medicines are in place by the end of 2017.
Healthcare providers are asked to keep up to date with local policies on switching to biosimilars, and should ensure that they know what they spend on biologic treatments. Finally, the framework also has a recommendation for patients: those receiving treatment with biologics should ask their healthcare providers if there are suitable biosimilar options that they may receive for treatment.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.